WO2022161593A1 - Médicament pour la cicatrisation accélérée des plaies - Google Patents

Médicament pour la cicatrisation accélérée des plaies Download PDF

Info

Publication number
WO2022161593A1
WO2022161593A1 PCT/EP2021/051696 EP2021051696W WO2022161593A1 WO 2022161593 A1 WO2022161593 A1 WO 2022161593A1 EP 2021051696 W EP2021051696 W EP 2021051696W WO 2022161593 A1 WO2022161593 A1 WO 2022161593A1
Authority
WO
WIPO (PCT)
Prior art keywords
peg
sodium
dimethicone
acid
ppg
Prior art date
Application number
PCT/EP2021/051696
Other languages
English (en)
Inventor
Uwe SCHAAR
Emilie Singer
Dominik Stuhlmann
Michael DOSSI
Marcus-Rudolf GÖTZ
Original Assignee
Symrise Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symrise Ag filed Critical Symrise Ag
Priority to PCT/EP2021/051696 priority Critical patent/WO2022161593A1/fr
Publication of WO2022161593A1 publication Critical patent/WO2022161593A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention refers to the area of pharmaceutical compositions and relates to specific medicaments for accelerating wound healing.
  • Wound healing refers to the body's endogenous process of closing a wound by restoring the damaged body tissue to the greatest possible extent. This is a natural biological process that begins only minutes after occurrence of the wound, as has been established by enzyme histochemical methods. The platelets are sent to the damaged site and attempt to close it. In some cases, scab formation occurs by exudation (secretion of fluid), which also causes the itching frequently accompanying wound healing.
  • Wound healing can be divided into various phases. Initially, after the destroyed blood vessel is closed by a clot, there are no further macroscopically or microscopically visible reactions. This first latency phase leads into an exudation phase, in which foreign bodies and bacteria are washed from the wound by wound secretion exuding from the wound. In this phase, the cells and hormones of the immune system play an essential role, not only in killing bacteria or viruses that have invaded the wound, but also in stimulating the healing process itself. In clot formation, a fibrin network is formed that acts as an adhesive to close adjacent margins of the wound. Clear wound secretion composed of serum is permeated with inflammatory cells. In the course of this phase, mitosis in the wound area increases.
  • Fibroblasts which develop from connective tissue cells that have infiltrated the wound, but are also present in the wound margin and reproduce by cell division, carry out the actual reconstruction work in the following phase.
  • the wound defect is increasingly filled by proliferation of new connective tissue.
  • the fibrin network is broken down (fibrinolysis) by plasmin.
  • Vascularization i.e. an increase in the number of blood vessels, takes place by capillary growth.
  • the fibroblasts produce hex- osamine-containing acidic mucopolysaccharides, which function as an extracellular base substance of the connective tissue and, via intracellular preliminary stages, form the final extracellular collagen connective tissue fibers.
  • the process over time is highly complex and is subject to the influence of numerous growth factors (cytokines).
  • the wound is closed at the surface by epithelializa- tion.
  • One-third of the diameter of a well-granulating wound closes exclusively by contraction, and the other two-thirds close due to reformation or cell division of epithelial cells and migration via fibrin from the wound margin to the center of the wound.
  • the underlying granulation tissue increasingly forms collagen fibers, after which restoration of all skin layers is virtually complete.
  • the further increase in the strength of the scar tissue depends on moistening, solidifying, and orientation of the collagen fibers.
  • the water content of the tissue decreases, and the scar, which initially protruded slightly above skin level, normally contracts to below skin level.
  • the vascularity of the scar tissue also decreases.
  • the originally fresh red scar turns white.
  • EP 0967980 Bl (YORK PHARMA) suggests substituted 2-aminothiazoles for promoting wound healing.
  • EP 1070058 Bl (PFIZER) relates to arylsulfoaminopyran carboxylic acid hydroxymides useful for accelerating wound healing and treating burns.
  • EP 1387838 Bl (BAYER) concerns anthranilamide pyridinamides as VEGFR-2 and VEGFR-3 inhibitors, their production and use as pharmaceutical agents for treating injuries
  • EP 1392354 Bl (BAYER) relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.
  • ACT alpha 1-antichymotrypsin
  • EP 1877396 Bl suggests novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for promoting wound healing.
  • CN 106511250 A (JINGXI YIXINTANG) suggests a complex mixture of low volatile essential oils for promoting wound gealing.
  • WO 2015 193262 Al (SYMRISE) relates to sandalore and brahmanol as medicaments for accelerated wound healing.
  • the object of the present invention has been identifying substance groups or concrete substances capable of promoting wound healing, preferably by accelerating wound coherence.
  • a first object of the present invention refers to a agonists of olfactory receptors selected from the group consisting of
  • Verdolea for use as a medicament for accelerating wound healing.
  • Olfactory receptors also known as odorant receptors, are expressed in the cell membranes of olfactory receptor neurons and are responsible for the detection of air-borne odour molecules that enter the nasal cavity. Activated olfactory receptors trigger nerve impulses which transmit information about odour to the brain. These receptors are members of the class A rhodopsin-like family of G protein-coupled receptors (G PC Rs). The olfactory receptors form a multigene family consisting of around 800 genes in humans. Particularly, the human nose has roughly 400 types of scent receptors that can detect at least 1 trillion different odours.
  • olfactory receptors display affinity for a range of odour molecules, and conversely a single odorant molecule may bind to a number of olfactory receptors with varying affinities, which depend on physio-chemical properties of molecules like their molecular volumes.
  • the receptor undergoes structural changes and it binds and activates the olfactory-type G protein on the inside of the olfactory receptor neuron.
  • the G protein (G o if and/or G s ) in turn activates the lyase - adenylate cyclase - which converts ATP into cyclic AMP (cAMP).
  • the cAMP opens cyclic nucleotide-gated ion channels which allow calcium and sodium ions to enter into the cell, depolarizing the olfactory receptor neuron and beginning an action potential which carries the information to the brain.
  • OR is the root name (Olfactory Receptor superfamily)
  • n an integer representing a family (e.g., 1-56) whose members have greater than 40% sequence identity
  • OR1A1 is the first isoform of subfamily A of olfactory receptor family.
  • An overview on olfactory receptors can be found in the following paper submitted by Gaillard I, Rouquier S, Giorgi: D "Olfactory receptors”. Cellular and Molecular Life Sciences. 61 (4): 456-69 (2004).
  • the evaporation rate is the rate at which a material will vaporize (evaporate, change from liquid to vapor) compared to the rate of vaporization of butyl acetate, which is set as 1. This quantity is a ratio, therefore it is unitless. Agonists of olfactory receptors
  • Suitable agonists according to the present invention are selected from the group consisting of:
  • Verdolea • Verdolea; and mixtures thereof.
  • Particularly preferred are rose oxide, aldehyde CIO, borneol, isoborneol, labdanum extract, verdolea and mixtures thereof.
  • the agonists can be applied in a concentration of from 0.1 to 100 pg/ml, and preferably of from 0.5 to 10 pg/ml.
  • Another object of the present invention refers to a cosmetic or pharmaceutical composition
  • a cosmetic or pharmaceutical composition comprising the agonists as defined above, preferably in amounts of from 0.0001 to about 1 wt. -percent, more preferably from about 0.001 to about 0.1 wt.-percent.
  • compositions may represent a lotion, a cream, an emulsion, an ointment or any other form for topical application on skin.
  • compositions may comprise a cosmetically or pharmaceutically acceptable carrier or solvent, such as for example water, ethanol, isopropyl alcohol, butanol, glycerol, ethylene glycol, propylene glycol and diethylene glycol or mixtures thereof.
  • a cosmetically or pharmaceutically acceptable carrier or solvent such as for example water, ethanol, isopropyl alcohol, butanol, glycerol, ethylene glycol, propylene glycol and diethylene glycol or mixtures thereof.
  • the carriers may be present in quantities of 99 wt. -percent, preferably 99.9 wt.- percent or more.
  • compositions may comprise at least one biogenic agent or antioxidant.
  • Biogenic active substances include, for example, tocopherol, tocopherol acetate, tocopherol palmitate, ascorbic acid, (deoxy)ribonucleic acid and its fragmentation products, [3-glucans, retinol, bisabolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudoceramides, essential oils, plant extracts, such as such as prunus extract, bambaranus extract and vitamin complexes.
  • Antioxidants interrupt the photochemical reaction chain which is triggered when UV radiation penetrates the skin.
  • Typical examples are amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides like D,L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. -carotene, lycopene) and their derivates, chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g.
  • thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamin and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, linoleyl, cholesteryl and glyceryl esters
  • Dilaurylthiodipropionate, ditearylthiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid gallic acid
  • bile extracts bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. linolenic acid, linoleic acid, oleic acid
  • folic acid and its derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and its derivatives e.g. ascorbyl palmitate, Mg-ascorbyl phosphate, ascorbylacetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • vitamin A and derivates vitamin A palmitate
  • conifer aryl benzoate of benzoic resin rutinic acid and its derivatives, glycosyl rutin, ferulic acid, furfurylidene glucitol, carnosine, butyl hydroxytoluene, butylhydroxyanisole, nordihydroguaiac resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, superoxide dismutase, zinc and its derivatives (e.g. e.g. ZnO, ZnSO4) selenium and its derivatives (e.g.
  • agonists according to the present invention are incorporated in or delivered to human skin by means of a cosmetic or pharmaceutical composition, these may contain further additives which are typical for skin care applications, as for example:
  • auxiliaries and additives are anionic and/or amphoteric or zwitterionic surfactants.
  • Non-ionic and cationic surfactants can be also present in the composition. Suitable examples are mentioned along with the paragraph dealing with emulsifiers.
  • Typical examples for anionic and zwitterionic surfactants encompass: Almondami- dopropylamine Oxide, Almondamidopropyl Betaine, Aminopropyl Laurylglutamine, Ammonium C12-15 Alkyl Sulfate, Ammonium C12-16 Alkyl Sulfate, Ammonium Capryleth Sulfate, Ammonium Cocomonoglyceride Sulfate, Ammonium Coco-Sulfate, Ammonium Cocoyl Isethionate, Ammonium Cocoyl Sarcosinate, Ammonium C12-15 Pareth Sulfate, Ammonium C9-10 Perfluoroalkylsulfonate, Ammonium Dinonyl Sulfosuccinate, Ammonium Dodecylbenzenesulfonate, Ammonium Isostearate, Ammonium Laureth-6 Carboxylate, Ammonium Lau- reth-8 Carboxylate, Ammonium Laureth Sulfate
  • the percentage content of surfactants in the preparations may be from 0.1 to 10% by weight and is preferably from 0.5 to 5% by weight, based on the preparation.
  • Suitable oil bodies which form constituents of the O/W emulsions, are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, esters of linear Ce-C22-fatty acids with linear or branched Ce-C22-fatty alcohols or esters of branched Ce-C 13-carboxylic acids with linear or branched Ce-C 22-fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, stearyl myristate, stearyl palmitate,
  • esters of linear Ce-C22-fatty acids with branched alcohols in particular 2-ethylhexanol
  • esters of C18-C38- alkylhydroxy carboxylic acids with linear or branched Ce-C 22-fatty alcohols in particular Dioctyl Malate
  • esters of linear and/or branched fatty acids with polyhydric alcohols such as, for example, propylene glycol, dimerdiol or trimertriol
  • Guerbet alcohols triglycerides based on Ce -Cio-fatty acids, liquid mono-/di triglyceride mixtures based on Ce-Cis-fatty acids
  • esters of Ce- C22-fatty alcohols and/or Guerbet alcohols with aromatic carboxylic acids in particular benzoic acid
  • Finsolv® TN linear or branched, symmetrical or asymmetrical dialkyl ethers having 6 to 22 carbon atoms per alkyl group, such as, for example, dicaprylyl ether (Cetiol® OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicones, silicone methicone grades, etc.) and/or aliphatic or naphthenic hydrocarbons, such as, for example, squalane, squalene or dialkylcyclohexanes.
  • dicaprylyl ether such as, for example, dicaprylyl ether (Cetiol® OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicones, silicone methicone grades, etc.) and/or aliphatic or naphthenic hydrocarbons, such as, for example, squalane, squalen
  • non-ionic or cationic surfactants may also be added to the preparations as emulsifiers, including for example:
  • polyol esters and, in particular, polyglycerol esters such as, for example, polyglycerol polyricinoleate, polyglycerol poly-12-hydroxystearate or polyglycerol dimerate isostearate. Mixtures of compounds from several of these classes are also suitable;
  • the addition products of ethylene oxide and/or propylene oxide onto fatty alcohols, fatty acids, alkylphenols, glycerol mono- and diesters and sorbitan mono- and diesters of fatty acids or onto castor oil are known commercially available products. They are homologue mixtures of which the average degree of alkoxylation corresponds to the ratio between the quantities of ethylene oxide and/or propylene oxide and substrate with which the addition reaction is carried out. C12/18 fatty acid monoesters and diesters of addition products of ethylene oxide onto glycerol are known as lipid layer enhancers for cosmetic formulations.
  • the preferred emulsifiers are described in more detail as follows:
  • Partial glycerides Typical examples of suitable partial glycerides are hydroxystearic acid monoglyceride, hydroxystearic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, oleic acid monoglyceride, oleic acid diglyceride, ricinoleic acid monoglyceride, ricinoleic acid diglyceride, linoleic acid monoglyceride, linoleic acid diglyceride, linolenic acid monoglyceride, linolenic acid diglyceride, erucic acid monoglyceride, erucic acid diglyceride, tartaric acid monoglyceride, tartaric acid diglyceride, citric acid monoglyceride, citric acid diglyceride, malic acid monoglyceride, malic acid diglyceride and technical mixtures thereof which may still contain small quantities of triglyceride, cit
  • Sorbitan esters are sorbitan monoisostearate, sorbitan ses- quiisostearate, sorbitan diisostearate, sorbitan triisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan sesquieru- cate, sorbitan dierucate, sorbitan trierucate, sorbitan monoricinoleate, sorbitan sesquiricino- leate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydroxystearate, sorbitan tri hydroxystea rate, sorbitan monotartrate, sorbitan sesquitartrate, sorbitan ditartrate, sorbitan tritart
  • Polyglycerol esters are Polyglyceryl- 2 Dipolyhydroxystearate (Dehymuls® PGPH), Polyglycerin-3-Diisostearate (Lameform® TGI), Polyglyceryl-4 Isostearate (Isolan® GI 34), Polyglyceryl-3 Oleate, Diisostearoyl Polyglyceryl-3 Diisostearate (Isolan® PDI), Polyglyceryl-3 Methylglucose Distearate (Tego Care® 450), Poly- glyceryl-3 Beeswax (Cera Beilina®), Polyglyceryl-4 Caprate (Polyglycerol Caprate T2010/90), Polyglyceryl-3 Cetyl Ether (Chimexane® NL), Polyglyceryl-3 Distearate (Cremophor® GS 32) and Polyglyceryl Polyricinoleate (Admul®
  • polystyrene resin examples include the mono-, di- and triesters of trimethylol propane or pentaerythritol with lauric acid, cocofatty acid, tallow fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid and the like optionally reacted with 1 to 30 mol ethylene oxide.
  • Cationically active surfactants comprise the hydrophobic high molecular group required for the surface activity in the cation by dissociation in aqueous solution.
  • a group of important representatives of the cationic surfactants are the tetraalkyl ammonium salts of the general formula: (R 1 R 2 R 3 R 4 N + ) X .
  • R1 stands for Ci-Cs alk(en)yl, R 2 , R 3 and R 4 , independently of each other, for alk(en)yl radicals having 1 to 22 carbon atoms.
  • X is a counter ion, preferably selected from the group of the halides, alkyl sulfates and alkyl carbonates.
  • Cationic surfactants, in which the nitrogen group is substituted with two long acyl groups and two short alk(en)yl groups are particularly preferred.
  • Esterquats A further class of cationic surfactants particularly useful as co-surfactants for the present invention is represented by the so-called esterquats.
  • Esterquats are generally understood to be quaternised fatty acid triethanolamine ester salts. These are known compounds which can be obtained by the relevant methods of preparative organic chemistry. Reference is made in this connection to International patent application WO 91/01295 Al, according to which triethanolamine is partly esterified with fatty acids in the presence of hypophosphorous acid, air is passed through the reaction mixture and the whole is then quaternised with dimethyl sulphate or ethylene oxide.
  • German patent DE 4308794 Cl describes a process for the production of solid esterquats in which the quaternisation of triethanolamine esters is carried out in the presence of suitable dispersants, preferably fatty alcohols.
  • suitable dispersants preferably fatty alcohols.
  • Typical examples of esterquats suitable for use in accordance with the invention are products of which the acyl component derives from monocarboxylic acids corresponding to formula RCOOH in which RCO is an acyl group containing 6 to 10 carbon atoms, and the amine component is triethanolamine (TEA).
  • monocarboxylic acids are caproic acid, caprylic acid, capric acid and technical mixtures thereof such as, for example, so- called head-fractionated fatty acid.
  • Esterquats of which the acyl component derives from monocarboxylic acids containing 8 to 10 carbon atoms are preferably used.
  • Other esterquats are those of which the acyl component derives from dicarboxylic acids like malonic acid, succinic acid, maleic acid, fumaric acid, glutaric acid, sorbic acid, pimelic acid, azelaic acid, sebacic acid and/or dodecanedioic acid, but preferably adipic acid.
  • esterquats of which the acyl component derives from mixtures of monocarboxylic acids containing 6 to 22 carbon atoms, and adipic acid are preferably used.
  • the molar ratio of mono and dicarboxylic acids in the final esterquat may be in the range from 1:99 to 99:1 and is preferably in the range from 50:50 to 90:10 and more particularly in the range from 70:30 to 80:20.
  • other suitable esterquats are quaternized ester salts of mono-/dicarboxylic acid mixtures with diethanolalkyamines or 1,2- dihydroxypropyl dialkylamines.
  • the esterquats may be obtained both from fatty acids and from the corresponding triglycerides in admixture with the corresponding dicarboxylic acids.
  • Superfatting agents may be selected from such substances as, for example, lanolin and lecithin and also polyethoxylated or acylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides, the fatty acid alkanolamides also serving as foam stabilizers.
  • the consistency factors mainly used are fatty alcohols or hydroxyfatty alcohols containing 12 to 22 and preferably 16 to 18 carbon atoms and also partial glycerides, fatty acids or hydroxyfatty acids.
  • a combination of these substances with alkyl oligoglucosides and/or fatty acid N-methyl glucamides of the same chain length and/or polyglycerol poly-12- hydroxystea rates is preferably used.
  • Suitable thickeners are polymeric thickeners, such as Aerosil® types (hydrophilic silicas), polysaccharides, more especially xanthan gum, guar-guar, agar-agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl cellulose, also relatively high molecular weight polyethylene glycol monoesters and diesters of fatty acids, polyacrylates (for example Carbo- pols® [Goodrich] or Synthalens® [Sigma]), polyacrylamides, polyvinyl alcohol and polyvinyl pyrrolidone, surfactants such as, for example, ethoxylated fatty acid glycerides, esters of fatty acids with polyols, for example pentaerythritol or trimethylol propane, narrow-range fatty alcohol ethoxylates and electrolytes, such as sodium chloride and ammonium chloride.
  • Aerosil® types hydrophilic silicas
  • Suitable cationic polymers are, for example, cationic cellulose derivatives such as, for example, the quaternized hydroxyethyl cellulose obtainable from Amerchol under the name of Polymer JR 400®, cationic starch, copolymers of diallyl ammonium salts and acrylamides, quaternized vinyl pyrrolidone/vinyl imidazole polymers such as, for example, Luviquat® (BASF), condensation products of polyglycols and amines, quaternized collagen polypeptides such as, for example, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen (Lamequat® L, Grunau), quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers such as, for example, amodimethicone, copolymers of adipic acid and dimethylaminohydroxypropyl diethylenetriamine (Carta retine®, Sandoz), copolymers of acrylic
  • Suitable anionic, zwitterionic, amphoteric and nonionic polymers are, for example, vinyl acetate/crotonic acid copolymers, vinyl pyrrolidone/vinyl acrylate copolymers, vinyl ace- tate/butyl maleate/isobornyl acrylate copolymers, methyl vinylether/maleic anhydride copolymers and esters thereof, uncrosslinked and polyol-crosslinked polyacrylic acids, acrylamido- propyl trimethylammonium chloride/acrylate copolymers, octylacrylamide/methyl methacry- late/tert.-butylaminoethyl methacrylate/2-hydroxypropyl methacrylate copolymers, polyvinyl pyrrolidone, vinyl pyrrolidone/vinyl acetate copolymers, vinyl pyrroli- done/dimethylaminoethyl methacrylate/vinyl caprol
  • Suitable pearlising waxes are, for example, alkylene glycol esters, especially ethylene glycol distearate; fatty acid alkanolamides, especially cocofatty acid diethanolamide; partial glycerides, especially stearic acid monoglyceride; esters of polybasic, optionally hydroxysubstituted carboxylic acids with fatty alcohols containing 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; fatty compounds, such as for example fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates which contain in all at least 24 carbon atoms, especially laurone and distea rylether; fatty acids, such as stearic acid, hydroxystearic acid or behenic acid, ring opening products of olefin epoxides containing 12 to 22 carbon atoms with fatty alcohols containing 12 to 22 carbon atoms and/or polyols containing 2 to 15 carbon
  • Suitable silicones can be chosen from the group consisting of: Acefylline Methylsilanol Mannuronate, Acetylmethionyl Methylsilanol Elastinate Acrylates/Behenyl, Acry- late/Dimethicone Methacrylate Copolymer, Acrylates/Behenyl Methacrylate/Dimethicone Methacrylate Copolymer, Acrylates/Bis-Hydroxypropyl Dimethicone Crosspolymer, Acry- lates/Dimethicone Copolymer, Acrylates/Dimethicone Methacrylate/Ethylhexyl Acrylate Copolymer, Acrylates/Dimethiconol Acrylate Copolymer, Acrylates/Ethylhexyl Acry- late/Dimethicone Methacrylate Copolymer, Acrylates/Octylacrylamide/Diphenyl Amodimethi-
  • Butyloxyamodimethicone/PEG-60 Copolymer Bis(C13-15 Alkoxy) Hydroxybutamidoamodi- methicone, Bis(C13-15 Alkoxy) PG- Amodimethicone, Bis-(Cl-8 Alkyl Lauroyl Lysine Decylcarboxamide) Dimethicone, Bis-Cetyl Cetyl Dimethicone, Bis-Cetyl/PEG-8 Cetyl PEG-8 Dimethicone, Bis-Diphenylethyl Disiloxane, Bis-Ethyl Ethyl Methicone, Bis- Gluconamidoethylaminopropyl Dimethicone, Bis-Hydrogen Dimethicone, Bis- Hydroxyethoxypropyl Dimethicone Bis-Hydroxylauryl, Dimethicone/IPDI Copolymer, Bis- Hydroxy/Methoxy Amodimethicone, Bis-Hy
  • silicones to be contained in the mixture according to the inventions are Dimethicone, Cyclomethicone, Phenyl Trimethicone, Cyclohexasiloxane and Cyclopentasiloxane.
  • Dimethicone Cyclomethicone
  • Phenyl Trimethicone Cyclohexasiloxane
  • Cyclopentasiloxane A detailed overview of suitable volatile silicones can be found in Todd et al. in Cosm. Toil. 91. 27 (1976).
  • waxes may also be present in the preparations, more especially natural waxes such as, for example, candelilla wax, carnauba wax, Japan wax, espartograss wax, cork wax, guaruma wax, rice oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, spermaceti, lanolin (wool wax), uropygial fat, ceresine, ozocerite (earth wax), petrolatum, paraffin waxes and microwaxes; chemically modified waxes (hard waxes) such as, for example, montan ester waxes, sasol waxes, hydrogenated jojoba waxes and synthetic waxes such as, for example, polyalkylene waxes and polyethylene glycol waxes.
  • natural waxes such as, for example, candelilla wax, carnauba wax, Japan wax, espartograss wax, cork wax, guarum
  • Metal salts of fatty acids such as, for example, magnesium, aluminium and/or zinc stearate or ricinoleate may be used as stabilizers.
  • Primary sun protection factors in the context of the invention are, for example, organic substances (light filters) which are liquid or crystalline at room temperature and which are capable of absorbing ultraviolet radiation and of releasing the energy absorbed in the form of longer-wave radiation, for example heat.
  • the formulations according to the invention advantageously contain at least one UV- A filter and/or at least one UV-B filter and/or a broadband filter and/or at least one inorganic pigment.
  • Formulations according to the invention preferably contain at least one UV-B filter or a broadband filter, more particularly preferably at least one UV-A filter and at least one UV-B filter.
  • Preferred cosmetic compositions preferably topical formulations according to the present invention comprise one, two, three or more sun protection factors selected from the group consistiung of 4-aminobenzoic acid and derivatives, salicylic acid derivatives, benzophenone derivatives, dibenzoylmethane derivatives, diphenyl acrylates, 3-imidazol-4-yl acrylic acid and esters thereof, benzofuran derivatives, benzylidene malonate derivatives, polymeric UV absorbers containing one or more organosilicon radicals, cinnamic acid derivatives, camphor derivatives, trianilino-s-triazine derivatives, 2-hydroxyphenylbenzotriazole derivatives, phenylbenzimidazole sulfonic acid derivatives and salts thereof, anthranilic acid menthyl esters, benzotriazole derivativesand indole derivatives.
  • sunscreen factors selected from the group consistiung of 4-aminobenzoic acid and derivatives, salicylic acid
  • UV filters cited below which can be used within the context of the present invention are preferred but naturally are not limiting.
  • UV filters which are preferably used are selected from the group consisting of
  • Broadband filters which are preferably combined with one or more compounds of formula (I) in a preparation according to the present invention are selected from the group consisting of
  • compositions can comprise further typical detergent and cleansing composition ingredients such as UV-A filters filters which are preferably combined with one or more compounds of formula (I) in a preparation according to the present invention are selected from the group consisting of
  • compositions can comprise further typical detergent and cleansing composition ingredients such as UV filters which are more preferably combined with one or more compounds of formula (I) in a preparation according to the present invention are selected from the group consisting of
  • menthyl anthranilate Nao Heliopan®MA
  • these preparations contain at least one UVA filter and/or at least one UVB filter and/or at least one inorganic pigment.
  • the preparations may be present here in various forms such as are conventionally used for sun protection preparations. Thus, they may be in form of a solution, an emulsion of the water-in-oil type (W/O) or of the oil-in-water type (O/W) or a multiple emulsion, for example of the water-in-oil-in- water type (W/O/W), a gel, a hydrodispersion, a solid stick or else an aerosol.
  • a formulation according to the invention contains a total amount of sunscreen agents, i.e. in particular UV filters and/or inorganic pigments (UV filtering pigments) so that the formulation according to the invention has a light protection factor of greater than or equal to 2 (preferably greater than or equal to 5).
  • sunscreen agents i.e. in particular UV filters and/or inorganic pigments (UV filtering pigments) so that the formulation according to the invention has a light protection factor of greater than or equal to 2 (preferably greater than or equal to 5).
  • UV filters and/or inorganic pigments UV filtering pigments
  • Secondary sun protection factors of the antioxidant type interrupt the photochemical reaction chain which is initiated when UV rays penetrate into the skin.
  • Typical examples are amino acids (for example glycine, histidine, tyrosine, tryptophane) and derivatives thereof, imidazoles (for example urocanic acid) and derivatives thereof, peptides, such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (for example anserine), carotinoids, carotenes (for example alphacarotene, beta-carotene, lycopene) and derivatives thereof, chlorogenic acid and derivatives thereof, liponic acid and derivatives thereof (for example dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (for example thioredoxine, glutathione, cysteine, cystine,
  • Advantageous inorganic secondary light protection pigments are finely dispersed metal oxides and metal salts which are also mentioned in WO 2005 123101 Al.
  • the total quantity of inorganic pigments, in particular hydrophobic inorganic micro-pigments in the finished cosmetic preparation according to the present invention is advantageously from 0.1 to 30% by weight, preferably 0.5 to 10.0% by weight, in each case based on the total weight of the preparation.
  • particulate UV filters or inorganic pigments which can optionally be hydrophobed, can be used, such as the oxides of titanium (TiCh), zinc (ZnO), iron (Fe2O3), zirconium (ZrO2), silicon (SiO2), manganese (e.g. MnO), aluminium (AI2O3), cerium (e.g. Ce2Os) and/or mixtures thereof.
  • compositions may also contain one or more substances with a physiological cooling effect (cooling agents), which are preferably selected here from the following list: menthol and menthol derivatives (for example L-menthol, D-menthol, racemic menthol, isomenthol, neoisomenthol, neomenthol) menthylethers (for example (I-menthoxy)-l,2-propandiol, (l-menthoxy)-2-methyl-l,2-propandiol, l-menthyl-methylether), menthylesters (for example menthylformiate, menthylacetate, menthylisobutyrate, menthyllactates, L-menthyl-L-lactate, L-menthyl-D-lactate, menthyl-(2-methoxy)acetate, menthyl-(2-methoxyethoxy)acetate, menthylpyroglutamate), menthylcarbonates (for example L-menthol
  • Suitable anti-microbial agents are, in principle, all substances effective against Grampositive bacteria, such as, for example, 4- hydroxybenzoic acid and its salts and esters, N-(4- chlorophenyl)-N'-(3,4- dichlorophenyl)urea, 2,4,4'-trichloro-2'-hydroxy-diphenyl ether (triclo- san), 4-chloro-3,5-dimethyl-phenol, 2,2'-methylenebis(6-bromo-4- chlorophenol), 3-methyl- 4-(l-methylethyl)phenol, 2-benzyl-4-chloro-phenol, 3-(4-chlorophenoxy)-l,2-propanediol, 3- iodo-2-propynyl butylcarbamate, chlorhexidine, 3,4,4'-trichlorocarbanilide (TTC), antibacterial fragrances, thymol, thyme oil, eugenol, oil of cloves, TTC), anti
  • Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the other classes of compounds listed in Appendix 6, Parts A and B of the Kosmetikverowski ("Cosmetics Directive").
  • compositions according to the present inventions are selected from the group of products for treatment, protecting, care and cleansing of the skin and/or hair or as a make-up product, preferably as a leave-on product (meaning that the one or more compounds of formula (I) stay on the skin and/or hair for a longer period of time, compared to rinse-off products, so that the moisturizing and/or anti-ageing and/or wound healing promoting action thereof is more pronounced).
  • the formulations according to the invention are preferably in the form of an emulsion, e.g. W/O (water-in-oil), O/W (oil-in-water), W/O/W (water-in-oil-in-water), O/W/O (oil- in-water-in-oil) emulsion, PIT emulsion, Pickering emulsion, emulsion with a low oil content, micro- or nanoemulsion, a solution, e.g.
  • a gel including hydrogel, hydrodispersion gel, oleogel
  • spray e.g. pump spray or spray with propellant
  • a foam or an impregnating solution for cosmetic wipes e.g. soap, synthetic detergent, liquid washing, shower and bath preparation, bath product (capsule, oil, tablet, salt, bath salt, soap, etc.), effervescent preparation, a skin care product such as e.g.
  • an emulsion as described above, ointment, paste, gel (as described above), oil, balsam, serum, powder (e.g. face powder, body powder), eau de perfume, eau de toilette, after-shave, a mask, a pencil, stick, roll-on, pump, aerosol (foaming, non-foaming or post-foaming), a deodorant and/or antiperspirant, mouthwash and mouth rinse, a foot care product (including keratolytic, deodorant), an insect repellent, a sunscreen, aftersun preparation, a shaving product, aftershave balm, pre- and aftershave lotion, a depilatory agent, a hair care product such as e.g.
  • shampoo including 2- in-1 shampoo, anti-dandruff shampoo, baby shampoo, shampoo for dry scalps, concentrated shampoo
  • conditioner hair tonic, hair water, hair rinse, styling creme, pomade, perm and setting lotion
  • hair spray e.g. gel or wax
  • hair smoothing agent detangling agent, relaxer
  • hair dye such as e.g. temporary direct-dyeing hair dye, semi-permanent hair dye, permanent hair dye, hair conditioner, hair mousse, eye care product, make-up, make-up remover or baby product.
  • the formulations according to the invention are particularly preferably in the form of an emulsion, in particular in the form of a W/O, O/W, W/O/W, O/W/O emulsion, PIT emulsion, Pickering emulsion, emulsion with a low oil content, micro- or nanoemulsion, a gel (including hydrogel, hydrodispersion gel, oleogel), a solution e.g. in oil (fatty oils or fatty acid esters, in particular C6-C32 fatty acid C2-C30 esters)) or silicone oil, or a spray (e.g. pump spray or spray with propellant).
  • a gel including hydrogel, hydrodispersion gel, oleogel
  • a solution e.g. in oil (fatty oils or fatty acid esters, in particular C6-C32 fatty acid C2-C30 esters)) or silicone oil
  • a spray e.g. pump spray or spray with propellant.
  • Auxiliary substances and additives can be included in quantities of 5 to 99 % b.w., preferably 10 to 80 % b.w., based on the total weight of the formulation.
  • the amounts of cosmetic or dermatological auxiliary agents and additives and perfume to be used in each case can easily be determined by the person skilled in the art by simple trial and error, depending on the nature of the particular product.
  • the preparations can also contain water in a quantity of up to 99 % b.w., preferably 5 to 80 % b.w., based on the total weight of the preparation INDUSTRIAL APPLICATION
  • Another object of the present invention refers to laminate or plaster into which the agonists according to the present invention are incorporated, for example by impregnation of the part of the laminate or plaster that is applied directly to the wound.
  • Another object of the present invention concerns a non-therapeutical method for accelerating wound healing comprising or consisting of the following steps:
  • the present invention also refers to the use of the agonists as explained above for accelerating wound healing.
  • the present invention also refers to the use of said agonists of olfactory receptors as cosmetic ingredients.
  • said agonists of olfactory receptors as cosmetic ingredients.
  • all preferred embodiments, ranges, combinations and compositions as described above are also valid with respective to the claimed industrial applications. Any repretition is therefor superfluous.
  • HaCaT cells (5xl0 4 ) were seeded in 96-well black plates and incubated for 24h. Then, medium was removed and the cells cultivated in OptiMEM, labeled with 50pM 2-NBDG (2-[N-(7-nitrobenz-2-oxa-l,3-diazol-4-yl) amino]-2-deoxy-D-glucose and treated with the test substances or the positive control with Rosiglitazone for 24 h. Medium was removed and the wells are carefully washed with PBS and incubated in PBS (lOOpl/well).
  • HaCaT cells were seeded in 96-well black plates at a density of 5xl0 4 cells/well, were treated as indicated with increasing concentrations of the compounds incubated for 24h and loaded with 2-NBDG.
  • the fluorescence of Rosiglitazone 80pM is taken as 100% of glucose uptake

Abstract

L'invention concerne un couple d'agonistes de récepteurs olfactifs, en particulier OR2AT4, présentant (i) un poids moléculaire allant d'environ 50 à environ 300 Daltons et (ii) un taux d'évaporation par rapport à l'acétate de butyle d'environ 3 à environ 15 pour une utilisation en tant que médicament pour accélérer la cicatrisation des plaies.
PCT/EP2021/051696 2021-01-26 2021-01-26 Médicament pour la cicatrisation accélérée des plaies WO2022161593A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/051696 WO2022161593A1 (fr) 2021-01-26 2021-01-26 Médicament pour la cicatrisation accélérée des plaies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/051696 WO2022161593A1 (fr) 2021-01-26 2021-01-26 Médicament pour la cicatrisation accélérée des plaies

Publications (1)

Publication Number Publication Date
WO2022161593A1 true WO2022161593A1 (fr) 2022-08-04

Family

ID=74553789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/051696 WO2022161593A1 (fr) 2021-01-26 2021-01-26 Médicament pour la cicatrisation accélérée des plaies

Country Status (1)

Country Link
WO (1) WO2022161593A1 (fr)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
WO1991001295A1 (fr) 1989-07-17 1991-02-07 Henkel Kommanditgesellschaft Auf Aktien Procede de fabrication de composes quaternaires de l'ammonium
DE4308794C1 (de) 1993-03-18 1994-04-21 Henkel Kgaa Verfahren zur Herstellung von festen Esterquats mit verbesserter Wasserdispergierbarkeit
EP0750606B1 (fr) 1994-03-18 1998-10-28 Henkel Kommanditgesellschaft auf Aktien Procede de production d'esters quaternaires
EP0998929A2 (fr) * 1998-10-05 2000-05-10 Hedonist Biochemical Technologies Co., Ltd. Compositions pharmaceutiques topiques cicatrisantes contenant du borneol et du gallate de bismuth
WO2002038537A1 (fr) 2000-11-10 2002-05-16 Haarmann & Reimer Gmbh Nouveaux composes indanylidene
EP1070058B1 (fr) 1998-04-10 2003-05-02 Pfizer Products Inc. Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
EP0967980B1 (fr) 1997-01-13 2003-05-02 BaFuS Marketing GmbH Utilisation d'aminothiazoles dans le traitement de plaies ou de la peau
WO2004026840A1 (fr) 2002-09-18 2004-04-01 Unilever Plc Derives de tetrahydropyrimidine-2-one et leurs utilisations
EP1392354B1 (fr) 2001-04-30 2005-03-09 Switch Biotech Aktiengesellschaft Utilisation de l'alpha 1-antichymotrypsine pour la preparation d'une composition pour le traitement, la prevention ou le diagnostique des plaies se cicatrisant difficilement associees au diabete
WO2005049553A1 (fr) 2003-11-21 2005-06-02 Givaudan Sa Carboxamides p-menthane a substitution n
WO2005123101A1 (fr) 2004-06-18 2005-12-29 Symrise Gmbh & Co. Kg Extrait de mures sauvages
EP1387838B1 (fr) 2001-05-08 2006-04-19 Schering Aktiengesellschaft Derives de cyanoanthranylamide et leur utilisation comme medicament
WO2007128723A1 (fr) 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg ANTAGONISTES DES RéCEPTEURS D'AH
EP1877396B1 (fr) 2005-04-28 2009-02-18 Bayer HealthCare AG Derives de 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one utilises en tant qu'inhibiteurs specifiques des hif-prolyl-4-hydroxylases pour traiter des maladies cardiovasculaires et hematologiques
EP2033688A2 (fr) 2007-08-20 2009-03-11 Symrise GmbH & Co. KG Dérivés d'acide oxalique et leur utilisation en tant que matières de refroidissement physiologiques
WO2015193262A1 (fr) 2014-06-19 2015-12-23 Symrise Ag Médicament destiné à accélérer la cicatrisation
WO2016200760A1 (fr) * 2015-06-12 2016-12-15 The Procter & Gamble Company Compositions de parfum et leurs utilisations
CN106511250A (zh) 2016-12-25 2017-03-22 江西宜信堂医疗科技有限公司 一种香水及其制备方法

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
WO1991001295A1 (fr) 1989-07-17 1991-02-07 Henkel Kommanditgesellschaft Auf Aktien Procede de fabrication de composes quaternaires de l'ammonium
DE4308794C1 (de) 1993-03-18 1994-04-21 Henkel Kgaa Verfahren zur Herstellung von festen Esterquats mit verbesserter Wasserdispergierbarkeit
EP0750606B1 (fr) 1994-03-18 1998-10-28 Henkel Kommanditgesellschaft auf Aktien Procede de production d'esters quaternaires
EP0967980B1 (fr) 1997-01-13 2003-05-02 BaFuS Marketing GmbH Utilisation d'aminothiazoles dans le traitement de plaies ou de la peau
EP1070058B1 (fr) 1998-04-10 2003-05-02 Pfizer Products Inc. Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
EP0998929A2 (fr) * 1998-10-05 2000-05-10 Hedonist Biochemical Technologies Co., Ltd. Compositions pharmaceutiques topiques cicatrisantes contenant du borneol et du gallate de bismuth
WO2002038537A1 (fr) 2000-11-10 2002-05-16 Haarmann & Reimer Gmbh Nouveaux composes indanylidene
DE10055940A1 (de) 2000-11-10 2002-05-29 Bayer Ag Neue Indanylidenverbindungen
EP1392354B1 (fr) 2001-04-30 2005-03-09 Switch Biotech Aktiengesellschaft Utilisation de l'alpha 1-antichymotrypsine pour la preparation d'une composition pour le traitement, la prevention ou le diagnostique des plaies se cicatrisant difficilement associees au diabete
EP1387838B1 (fr) 2001-05-08 2006-04-19 Schering Aktiengesellschaft Derives de cyanoanthranylamide et leur utilisation comme medicament
WO2004026840A1 (fr) 2002-09-18 2004-04-01 Unilever Plc Derives de tetrahydropyrimidine-2-one et leurs utilisations
WO2005049553A1 (fr) 2003-11-21 2005-06-02 Givaudan Sa Carboxamides p-menthane a substitution n
WO2005123101A1 (fr) 2004-06-18 2005-12-29 Symrise Gmbh & Co. Kg Extrait de mures sauvages
EP1877396B1 (fr) 2005-04-28 2009-02-18 Bayer HealthCare AG Derives de 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one utilises en tant qu'inhibiteurs specifiques des hif-prolyl-4-hydroxylases pour traiter des maladies cardiovasculaires et hematologiques
WO2007128723A1 (fr) 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg ANTAGONISTES DES RéCEPTEURS D'AH
EP2033688A2 (fr) 2007-08-20 2009-03-11 Symrise GmbH & Co. KG Dérivés d'acide oxalique et leur utilisation en tant que matières de refroidissement physiologiques
WO2015193262A1 (fr) 2014-06-19 2015-12-23 Symrise Ag Médicament destiné à accélérer la cicatrisation
WO2016200760A1 (fr) * 2015-06-12 2016-12-15 The Procter & Gamble Company Compositions de parfum et leurs utilisations
CN106511250A (zh) 2016-12-25 2017-03-22 江西宜信堂医疗科技有限公司 一种香水及其制备方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Cistus essential oil, Essential Oils for skincare", 1 January 2021 (2021-01-01), XP055859021, Retrieved from the Internet <URL:https://www.decleor.com/en/oil-effects/anti-inflamatory/cistus.html> [retrieved on 20211108] *
DE SOUZA SIQUEIRA BARRETO ROSANA ET AL: "EFEITO CICATRIZANTE DO (-)-BORNEOL INCORPORADO AO FILME BIOATIVO DE QUITOSANA EM ROEDORES", 1 January 2013 (2013-01-01), XP055860197, Retrieved from the Internet <URL:https://ri.ufs.br/bitstream/riufs/3575/1/ROSANA_SOUZA_SIQUEIRA_BARRETO.pdf> [retrieved on 20211111] *
DUROUX ROMAIN ET AL: "A Rose Extract Protects the Skin against Stress Mediators: A Potential Role of Olfactory Receptors", MOLECULES, vol. 25, no. 20, 16 October 2020 (2020-10-16), pages 4743, XP055860195, DOI: 10.3390/molecules25204743 *
GAILLARD IROUQUIER SGIORGI: D: "Olfactory receptors", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 61, no. 4, 2004, pages 456 - 69
NASCIMENTO-JÚNIOR BRAZ JOSÉ DO ET AL: "Anti-inflammatory and healing action of oral gel containing borneol monoterpene in chemotherapy-induced mucositis in rats ( Rattus norvegicus )", BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 53, no. 3, 31 July 2017 (2017-07-31), pages 81, XP055860198, Retrieved from the Internet <URL:https://www.scielo.br/j/bjps/a/Z4kXmB9xXyKcCdtwPsC5bhz/?format=pdf&lang=en> DOI: 10.1590/s2175-97902017000300081 *
TODD ET AL., COSM. TOIL., vol. 91, 1976, pages 27
VERZEAUX L. ET AL: "Structure-function relationship between a natural cosmetic active ingredient and the olfactory receptor OR2AT4", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE., vol. 41, no. 2, 29 March 2019 (2019-03-29), NL, pages 194 - 199, XP055827113, ISSN: 0142-5463, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ics.12526> DOI: 10.1111/ics.12526 *

Similar Documents

Publication Publication Date Title
US11723850B2 (en) Liquid and transparent blend of UV filters
US20220117881A1 (en) A hair care composition
EP3993767A1 (fr) Mélange de cire d&#39;abeille et d&#39;un ester de lactylate
WO2022122136A1 (fr) Compositions comprenant un ou plusieurs (bio)-alcanediols avec des antioxydants
US20230338250A1 (en) Compositions Comprising One or More (Bio)-Alkanediols with Active Ingredients
WO2022161593A1 (fr) Médicament pour la cicatrisation accélérée des plaies
US20220332771A1 (en) Plant peptides and their applications (ii)
WO2022111793A1 (fr) Médicament destiné à accélérer la cicatrisation
WO2022122122A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine (i)
WO2022122167A1 (fr) Médicament pour la prévention ou le traitement d&#39;états pathologiques de la peau humaine (i)
WO2022128054A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine (iv)
WO2022128052A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine
WO2022128051A1 (fr) Médicament pour lutter contre des états inflammatoires de la peau humaine (ii)
WO2022128050A1 (fr) Médicament pour lutter contre l&#39;inflammation et la douleur
WO2022128048A1 (fr) Médicament pour la prévention ou le traitement d&#39;états pathologiques de la peau humaine
EP4291154A1 (fr) Médicament pour la prévention et le traitement de l&#39;hyperpigmentation
EP4245291A1 (fr) Additif pour écrans solaires
EP4245292A1 (fr) Additif pour écrans solaires
WO2022128057A1 (fr) Médicament pour la prévention et le traitement de la dégradation du collagène dans un tissu conjonctif humain
WO2022111829A1 (fr) Huiles essentielles d&#39;agrumes destinées à être utilisées comme médicament pour obtenir une autophagie induite, augmentée et/ou accélérée dans des kératinocytes humains
WO2023175129A1 (fr) Additif pour écrans solaires
WO2024061476A1 (fr) Méthode pour prévenir, atténuer et/ou traiter des affections cutanées induites par ptgs2 et des dysfonctions associées
EP4259287A1 (fr) Procédé de lutte contre les micro-organismes utilisant des dérivés du menthol
WO2022218505A1 (fr) Mélange de parfum à base d&#39;isocitronellol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21703376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21703376

Country of ref document: EP

Kind code of ref document: A1